The clinical response to ONCOFID-P-B™ in bladder CIS likely relies on several components of the TME, and the combined evaluation of intra-tumoral macrophages density and CD44v6 expression is a potentially new predictive biomarker for patient response. Overall, our data allow to advance a potential rationale for combinatorial treatments targeting the immune infiltrate such as immune checkpoint inhibitors, to make bladder CIS more responsive to ONCOFID-P-B™ treatment.

8 months ago

Journal • IO biomarker

CD8 (cluster of differentiation 8) • ICAM1 (Intercellular adhesion molecule 1)

CD44 expression

paclitaxel • Oncofid-P (paclitaxel-hyaluronic acid conjugate)

1year

Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID) (clinicaltrials.gov)

P3, N=112, Recruiting, Fidia Farmaceutici s.p.a.

1 year ago

Trial completion date • Trial primary completion date

paclitaxel • Oncofid-P (paclitaxel-hyaluronic acid conjugate)

3years

Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: Results of a prospective European Multicentre study at 15 months from treatment start. (PubMed, Urol Oncol)

Oncofid-P-B is very safe, well tolerated and highly effective (75% CR) when administered weekly for up to 12 consecutive weeks (75% CR), with 40% CR still after 15 months from treatment start.

3 years ago

Clinical • Journal

CD44 (CD44 Molecule)

paclitaxel • Oncofid-P (paclitaxel-hyaluronic acid conjugate)

over3years

Simultaneous Targeting Tumor Cells and Cancer-Associated Fibroblasts with a Paclitaxel-Hyaluronan Bioconjugate: In Vitro Evaluation in Non-Melanoma Skin Cancer. (PubMed, Biomedicines)

Collectively, our data demonstrate that Onco-P20, exerting both a direct and an NHF-mediated indirect effect on carcinoma cells, is a candidate for an innovative therapy alternative to surgery for the treatment of NMSC.

over 3 years ago

Preclinical • Journal

CD44 (CD44 Molecule)

CD44 expression

paclitaxel • Oncofid-P (paclitaxel-hyaluronic acid conjugate)